shutterstock_1173953113_360b

360b / Shutterstock.com

2 May 2019Big Pharma

AstraZeneca partners on AI drug discovery collaboration

AstraZeneca has begun collaborating with UK-headquartered artificial intelligence (AI) company BenevolentAI to use AI and machine learning for the discovery and development of new treatments.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Novartis enters AI partnership with Oxford University

21 January 2019 Novartis and the University of Oxford’s Big Data Institute have joined forces to use artificial intelligence for improving drug development, initially in the areas of multiple sclerosis, dermatology and rheumatology.

Novartis and BenevolentAI sign AI oncology deal

9 September 2019 Swiss pharmaceutical company Novartis has united with BenevolentAI to aid in the discovery and development of new treatments.

AstraZeneca announces new R&D, AI centres in China

11 November 2019 AstraZeneca is planning to build a new global research and development centre in China.

More on this story

Novartis enters AI partnership with Oxford University

21 January 2019 Novartis and the University of Oxford’s Big Data Institute have joined forces to use artificial intelligence for improving drug development, initially in the areas of multiple sclerosis, dermatology and rheumatology.

Novartis and BenevolentAI sign AI oncology deal

9 September 2019 Swiss pharmaceutical company Novartis has united with BenevolentAI to aid in the discovery and development of new treatments.

AstraZeneca announces new R&D, AI centres in China

11 November 2019 AstraZeneca is planning to build a new global research and development centre in China.

More on this story

Novartis enters AI partnership with Oxford University

21 January 2019 Novartis and the University of Oxford’s Big Data Institute have joined forces to use artificial intelligence for improving drug development, initially in the areas of multiple sclerosis, dermatology and rheumatology.

Novartis and BenevolentAI sign AI oncology deal

9 September 2019 Swiss pharmaceutical company Novartis has united with BenevolentAI to aid in the discovery and development of new treatments.

AstraZeneca announces new R&D, AI centres in China

11 November 2019 AstraZeneca is planning to build a new global research and development centre in China.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent